Cardiac Calcium Channel Blocker Therapy represents a fundamental aspect of cardiovascular care, offering a targeted approach to managing heart-related conditions. These blockers, recognized as calcium antagonists, exert their therapeutic effects by impeding the entry of calcium ions into cardiac muscle cells. This mechanism proves particularly valuable in addressing diverse cardiovascular issues, ranging from hypertension and angina to specific arrhythmias. By facilitating the dilation of blood vessels and promoting cardiac relaxation, calcium channel blockers contribute to improved blood flow and reduced strain on the heart. The incorporation of these medications into a comprehensive treatment strategy underscores their role in optimizing cardiovascular health. It remains imperative for healthcare professionals to personalize prescriptions based on individual patient profiles, ensuring that the therapeutic benefits are maximized while mitigating potential side effects. The dynamic landscape of Cardiac Calcium Channel Blocker Therapy remains a driving force in advancing cardiovascular medicine and elevating the standard of care for individuals with heart-related conditions.
Title : Investigating the long-term follow up of atrial septal device closures in wales and england: A comparative analysis with major adverse cardiovascular Events (MACE)
Meera Gopinath, Cardiff University Medical school, United Kingdom
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Yasser’s criterion of inferior ST-segment discrepancy deviations in AF with aberrancy and Sgarbosa criteria - a new cardiovascular discovery and management - a case report
Yasser Mohammed Hassanain Elsayed, Egyptian Ministry of Health, Egypt
Title : Successful treatment of sinus of valsalva aneurysm
Aina Jarillo, Universidad Anahuac Mexico Norte, Mexico